Endo: End Game And What Burned Investors Can Learn

Stock Information for null

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About null

Endo Presents New Data at the American Orthopaedic Foot & Ankle Society Annual Meeting
ENDO REPORTS SECOND-QUARTER 2023 FINANCIAL RESULTS
Endo Launches PREVDUO(TM) (neostigmine methylsulfate and glycopyrrolate injection), the First and Only FDA-Approved Neostigmine-Glycopyrrolate Combination Pre-Filled Syringe
Endo Launches Authorized Generic Version of Noxafil® (posaconazole) Oral Suspension
Endo Enters Into Restructuring Support Agreement with Senior Secured Debtholders to Strengthen Financial Position and Advance Ongoing Business Transformation
New Drug Filing for Cenobamate Accepted for Review in Canada and Israel
ENDO REPORTS SECOND-QUARTER 2022 FINANCIAL RESULTS
Paladin Labs Announces Health Canada's Filing Acceptance of Cenobamate Tablets as an Adjunctive Therapy for the Management of Partial-Onset Seizures in Adults with Epilepsy

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.